Trial document
This study has been imported from ClinicalTrials.gov without additional data checks.
DRKS00006394
Trial Description
Title
A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period
Trial Acronym
[---]*
URL of the Trial
[---]*
Brief Summary in Lay Language
The purpose of this study is to evaluate the safety, tolerability and efficacy of NRL001 in
the treatment of faecal incontinence, compared against placebo
Brief Summary in Scientific Language
[---]*
Do you plan to share individual participant data with other researchers?
[---]*
Description IPD sharing plan:
[---]*
Organizational Data
- DRKS00006394
- 2014/08/28
- 2012/08/01
- no
- [---]*
- [---]*
Secondary IDs
- NCT01656720 (ClinicalTrials.gov)
- NRL001-01/2011 (SEFI) (Norgine)
Health Condition or Problem studied
- Faecal Incontinence
- R15 - Faecal incontinence
Interventions/Observational Groups
- Drug: 1R, 2S-methoxamine hydrochloride
- Drug: Placebo
Characteristics
- Interventional
- [---]*
- Randomized controlled trial
- Blinded
- patient/subject, investigator/therapist
- Placebo, Active control
- Treatment
- Parallel
- II
- [---]*
Primary Outcome
- Evaluate the efficacy of NRL001 in faecal incontinence by assessing the improvement of the incontinence status after 4 weeks of treatment compared to baseline by means of the Wexner score; time frame: Up to 8 weeks
Secondary Outcome
- To provide data on the efficacy of NRL001 in patients with faecal incontinence over an 8 week treatment period; time frame: 8 weeks
- To provide preliminary data on the safety and tolerability of NRL001 (5mg, 7.5mg and 10mg) over an 8 week treatment period compared to placebo; time frame: 8 weeks
- To evaluate the population pharmacokinetics and to establish any pharmacokinetic/pharmacodynamic relationship with adverse events; time frame: 8 weeks
- To evaluate the dose-response relationship in order to identify the appropriate dose(s) of NRL001 for future studies; time frame: 8 weeks
- To evaluate the effect of treatment according to the patient's Faecal Incontinence Quality of Life questionnaire at 4 and 8 weeks; time frame: 8 weeks
- To evaluate the effect of treatment according to the Vaizey score at 4 and 8 weeks; time frame: 8 weeks
Countries of Recruitment
- Czech Republic
- France
- Germany
- Hungary
- Italy
- Poland
- Spain
- Sweden
- United Kingdom
Locations of Recruitment
Recruitment
- [---]*
- 2012/02/27
- 580
- Multicenter trial
- International
Inclusion Criteria
- Both, male and female
- 18 Years
- no maximum age
Additional Inclusion Criteria
- An ultrasound assessment of the internal anal sphincter within the previous 12 months
confirming an intact circular internal sphincter with minimal scars (maximum 60
degrees scarring circumferentially).
- Diagnosis of faecal incontinence with a Wexner score of 8 - 20 inclusive at Visit 1 -
Screening Visit.
- Historical clinical evidence (past 6 months prior to Visit 1 - Screening Visit) of
faecal incontinence episodes (solids, liquid, gas or mucus).
- Greater than or equal to two faecal incontinence episodes (solids, liquid, gas or
mucus) per week during the 4 week historical period prior to Visit 1 - Screening
Visit.
- Able and willing to receive rectal examinations and treatments.
- Patients must be aged >18 without significant acute or uncontrolled chronic disease.
- Patients must understand the purpose and risks of the study and be able to provide
written informed consent and willing, able and competent to complete the entire study
and comply with study instructions as defined in the protocol.
- Female patients must be postmenopausal (for at least one year and confirmed by serum
FSH at screening), or surgically sterile, practicing true sexual abstinence, or using
Investigator-approved methods of contraception throughout the study until after the
post study physical examination and have a negative pregnancy test at screening.
- Sexually active male patients must use condoms with their partners throughout the
study and for 90 days after completion of the study in addition to their partner's
normal mode of contraception.
- Male patients must not donate sperm during the study and for 90 days after the
completion of the study.
- Patients taking any continuous medication need to have been on a stable regimen for
at least 1 month prior to Visit 1 - Screening Visit.
Exclusion Criteria
- External anal sphincter disruption related to faecal incontinence caused by trauma.
- Patients with complicating gastrointestinal (GI) disease including those with
inflammatory bowel diseases, patients that have received radiotherapy or surgery for
anal cancer, patients with rectal prolapse, transanal surgery.
- Relevant history of or presence of any significant or uncontrolled cardiovascular
risk including:
1. Systolic > 160mmHg or Diastolic > 100mmHg. Patients on a stable regimen for > 3
months with controlled hypertension prior to Visit 1 - Screening Visit (Systolic
< 140mmHg or Diastolic < 90mmHg) can be included.
2. Abnormal 24 hour Screening Holter: corrected QT interval (QTcf) prolongation
with cut-off values of >460 ms for females and >430 ms for males, acute
arrhythmia, nocturnal bradycardia with heart rate (HR) < 40bpm, atrial
fibrillation, AV block Type II and III, Sick Sinus Syndrome, vasovagal syncope.
3. Fixed cardiac output states (severe aortic stenosis (AS), hypertrophic
obstructive cardiomyopathy (HOCM).
4. Significant mitral regurgitation (MR).
5. Cardiac failure (New York Heart Association (NYHA) stage II-IV).
- Severe or uncontrolled asthma or chronic obstructive pulmonary disease determined by
clinical history, physical examination, lung function tests or exercise tolerance
- Chronic liver disease (e.g. liver cirrhosis, chronic hepatitis, severe hepatic
insufficiency).
- Vascular claudication after <50 metres walking distance.
- Severe renal impairment defined as glomerular filtration rate (GFR) ≤ 30 ml/min,
uncontrolled and reno-vascular end stage renal disease.
- Patients with diabetic polyneuropathies.
- Any type of chronic diarrhoea or frequent diarrhoea (defined as >5 loose stools per
day).
- Faecal impaction and overflow diarrhoea.
- Male patients with clinically diagnosed prostatic hyperplasia.
- Clinically significant electrolyte abnormalities, e.g. clinically significant
low/high potassium and low sodium.
- Presence of clinical symptomatic haemorrhoids (grade III and IV), anal fissures or
anorectal fistulas.
- Less than 2 episodes of faecal incontinence (solids, liquid, gas or mucus) per week
during the 4 week historical period prior to Visit 1 - Screening Visit.
- Participation in a clinical drug study during the 90 days preceding the initial dose
in this study.
- Known history of allergy to methoxamine or any other ingredients of the
Investigational Medicinal Product.
- Patients who, in the opinion of the Investigator, are unsuitable for participation in
the study due to any dependencies, general medical conditions or significant illness
within two weeks prior to randomisation.
- Use of any disallowed concomitant medication or other medication that the
Investigator believes may affect the study including over-the-counter (OTC) products
within 30 days prior to the Investigational Medicinal Product administration.
- A personal or family history of QTcf prolongation or sudden death.
- Patients taking Loperamide (2mg) >8 tablets per day for faecal incontinence either
alone or in combination with codeine phosphate and/or paracetamol (8/500mg).
- Patients using any device for the treatment of faecal incontinence.
Addresses
-
start of 1:1-Block address primary-sponsor
- Norgine
end of 1:1-Block address primary-sponsorstart of 1:1-Block address contact primary-sponsor- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact primary-sponsor -
start of 1:1-Block address scientific-contact
- Hopital Pontchaillou
- Laurent Siproudhis, MD
end of 1:1-Block address scientific-contactstart of 1:1-Block address contact scientific-contact- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact scientific-contact -
start of 1:1-Block address public-contact
- Deborah J Jones, BSc(Hons)
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- +44189582
- [---]*
- djones3 at norgine.com
- [---]*
end of 1:1-Block address contact public-contact
Sources of Monetary or Material Support
-
start of 1:1-Block address materialSupport
- Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
end of 1:1-Block address materialSupportstart of 1:1-Block address contact materialSupport- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact materialSupport
Status
- Recruiting ongoing
- [---]*
Trial Publications, Results and other Documents
- [---]*
- 2
- 2014/11/27